- Home
- SKYE vs OGI Comparison
SKYE vs OGI Comparison
Compare SKYE & OGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- OGI
- Stock Information
- Founded
- SKYE 2012
- OGI 2013
- Country
- SKYE United States
- OGI Canada
- Employees
- SKYE N/A
- OGI N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- OGI Biotechnology: Pharmaceutical Preparations
- Sector
- SKYE Health Care
- OGI Health Care
- Exchange
- SKYE Nasdaq
- OGI Nasdaq
- Market Cap
- SKYE 94.0M
- OGI 200.6M
- IPO Year
- SKYE N/A
- OGI N/A
- Fundamental
- Price
- SKYE $2.73
- OGI $1.53
- Analyst Decision
- SKYE Buy
- OGI
- Analyst Count
- SKYE 6
- OGI 0
- Target Price
- SKYE $18.67
- OGI N/A
- AVG Volume (30 Days)
- SKYE 167.7K
- OGI 820.8K
- Earning Date
- SKYE 02-09-2025
- OGI 02-11-2025
- Dividend Yield
- SKYE N/A
- OGI N/A
- EPS Growth
- SKYE N/A
- OGI N/A
- EPS
- SKYE N/A
- OGI N/A
- Revenue
- SKYE N/A
- OGI $118,317,480.00
- Revenue This Year
- SKYE N/A
- OGI $57.65
- Revenue Next Year
- SKYE N/A
- OGI $10.93
- P/E Ratio
- SKYE N/A
- OGI N/A
- Revenue Growth
- SKYE N/A
- OGI 0.69
- 52 Week Low
- SKYE $2.25
- OGI $1.31
- 52 Week High
- SKYE $19.41
- OGI $2.91
- Technical
- Relative Strength Index (RSI)
- SKYE 37.40
- OGI 44.32
- Support Level
- SKYE $2.31
- OGI $1.56
- Resistance Level
- SKYE $3.04
- OGI $1.77
- Average True Range (ATR)
- SKYE 0.30
- OGI 0.08
- MACD
- SKYE 0.07
- OGI -0.00
- Stochastic Oscillator
- SKYE 44.68
- OGI 11.11
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About OGI Organigram Holdings Inc.
OrganiGram Holdings Inc is engaged in producing indoor-grown cannabis for patients and adult recreational consumers in Canada. The company has also developed a portfolio of adult-use recreational cannabis brands including Edison, Big Bag o' Buds, SHRED, Monjour, Holy Mountain, and Trailblazer. Tremblant Cannabis, and artisanal craft brand, Laurentian are recent additions to Organigram's existing brand portfolio.